Home » Agilent Pathology Solution Receives CE Mark for Device
Agilent Pathology Solution Receives CE Mark for Device
This new companion diagnostic device has earned a CE Mark from the EU.
This diagnostic device, PD-L1 IHC 22C3, can reveal whether a patient with advanced non-small cell lung cancer is likely to respond to keytruda, an anti-PD-1 therapy.
This diagnostic device was approved for use in the United States last year. — Cynthia Jessup
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May